PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6017719

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
SIENNA BIOPHARMACEUTICALS, INC.	12/05/2019

RECEIVING PARTY DATA

Name:	SEBACIA, INC.
Street Address:	2905 PREMIERE PARKWAY SUITE 150
City:	DULUTH
State/Country:	GEORGIA
Postal Code:	30097

PROPERTY NUMBERS Total: 27

Property Type	Number
Application Number:	61402305
Application Number:	61422612
Application Number:	61516308
Application Number:	13219514
Application Number:	14020423
Application Number:	14020387
Application Number:	14020481
Application Number:	14020599
Application Number:	14471348
Application Number:	14471377
Application Number:	14471330
Application Number:	14471319
Application Number:	14471434
Application Number:	14471350
Application Number:	14471331
Application Number:	14471268
Application Number:	14471367
Application Number:	14471402
Application Number:	14471437
Application Number:	14471429

PATENT REEL: 052138 FRAME: 0380

505971011

Property Type	Number
Application Number:	61870103
Application Number:	14321509
Application Number:	14681379
Application Number:	14947508
PCT Number:	US2013063920
PCT Number:	US2011049464
PCT Number:	US2014052266

CORRESPONDENCE DATA

Fax Number: (214)866-0010

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2148660001

Email: kthiesse@chalkerflores.com

Correspondent Name: EDWIN FLORES C/O CHALKER FLORES LLP 4951 NORTH DALLAS PARKWAY, SUITE 400

Address Line 4: DALLAS, TEXAS 75254

ATTORNEY DOCKET NUMBER:	SEBA:6000
NAME OF SUBMITTER:	KAREN THIESSE
SIGNATURE:	/Karen Thiesse/
DATE SIGNED:	03/17/2020

Total Attachments: 19

source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page1.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page2.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page3.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page4.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page5.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page6.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page7.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page8.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page9.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page10.tif source=SBP IP Assignment Agreement [Executed]_112096616_2_0#page11.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page12.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page13.tif source=SBP IP Assignment Agreement [Executed]_112096616_2_0#page14.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page15.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page16.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page17.tif source=SBP IP Assignment Agreement [Executed] 112096616_2_0#page18.tif source=SBP IP Assignment Agreement [Executed] 112096616 2 0#page19.tif

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

THIS INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT (this "Assignment Agreement") is made and entered into as of December 5, 2019, by and among Sienna Biopharmaceuticals, Inc., a Delaware corporation (the "Seller") and Sebacia, Inc. (the "Buyer"). The Seller and the Buyer are collectively referred to herein as the "Parties" and individually as a "Party."

WHEREAS, the Seller and the Buyer are parties to that certain Asset Purchase Agreement, dated as of December 5, 2019 (as amended, restated, supplemented, or otherwise modified from time to time, the "Purchase Agreement"), pursuant to which the Buyer has agreed to purchase from the Seller, and the Seller has agreed to sell to the Buyer, the Purchased Assets, and the Buyer has agreed to assume from the Seller certain specified liabilities, in each case pursuant to the terms and subject to the conditions set forth in the Purchase Agreement and further subject to Orders by the Bankruptcy Court in the Bankruptcy Case; and

WHEREAS, in connection with the Closing of the transactions contemplated by the Purchase Agreement, each of the Seller and the Buyer has agreed to deliver this Agreement to the other Party.

NOW, THEREFORE, in accordance with the Purchase Agreement and in consideration of the premises and the mutual covenants and agreements contained herein and therein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Seller and the Buyer, intending to be legally bound, hereby agree as follows:

ASSIGNMENT

Section 1. <u>Definitions</u>. Capitalized terms used but not defined in this Assignment Agreement shall have the meanings assigned thereto in the Purchase Agreement.

Section 2. <u>Assignment</u>.

- (a) Upon the terms contained in the Purchase Agreement and pursuant to the terms of the Sale Order, the Seller hereby sells, assigns, conveys, transfers, and delivers to the Buyer and its successors and assigns, effective as of the Closing, all of the Seller's right, title, and interest, free and clear of all Liens (other than the Permitted Liens), in and to all of the Acquired Program IP (including, but not limited to, all of the Acquired Program IP set forth on Schedule 1 hereto), together with any and all goodwill in connection therewith.
- (b) The assignments described in this Section 2 include all claims (including claims for past infringement or misappropriation of Acquired Program IP) and causes of action (other than, in each case, to the extent solely related to Excluded Assets or Excluded Liabilities) of the Seller as of the Closing against any and all Persons (regardless of whether or not such claims and causes of action have been asserted by the Seller) and all rights of indemnity, warranty rights, rights of contribution, rights to refunds, rights of reimbursement, and other rights of recovery, including rights to insurance proceeds (other than amounts attributable to the

US-DOCS\112008977.2

Excluded Insurance Policies), possessed by the Seller as of the Closing (regardless of whether such rights are currently exercisable) to the extent related to the Acquired Program IP.

- **Section 3.** <u>Liabilities not Assumed</u>. The Buyer shall not assume or be obligated to pay, perform, or otherwise discharge any of the Excluded Liabilities.
- **Section 4.** Terms of the Purchase Agreement. Each of the Seller and the Buyer acknowledges and agrees that the representations, warranties, and agreements contained in the Purchase Agreement, and any limitations thereto, shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. This Assignment Agreement is subject in all respects to the terms of the Purchase Agreement and, in the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern.
- **Section 5.** <u>Succession and Assignment</u>. This Agreement and all of the provisions hereof shall be binding upon, inure to the benefit of and be enforceable by the Parties and their respective successors and permitted assigns, including, in the case of the Seller, any trustee in the Bankruptcy Case (or in a case under Chapter 7 of the Bankruptcy Code); *provided*, *however*, that no assignment by any Party shall relieve such Party of any of its obligations hereunder.
- **Section 6.** Governing Law. Except to the extent the mandatory provisions of the Bankruptcy Code apply, this Assignment Agreement, and all claims and causes of action arising out of, based upon, or related to this Assignment Agreement or the negotiation, execution, or performance hereof, shall be governed by, and construed, interpreted, and enforced in accordance with, the Laws of the State of Delaware, without regard to choice or conflict of law principles that would result in the application of any Laws other than the Laws of the State of Delaware.
- **Section 7.** <u>Headings</u>. The section headings contained in this Assignment Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Assignment Agreement.
- **Section 8.** Counterparts and Facsimile Signature. This Assignment Agreement may be executed by facsimile or pdf format and in one or more counterparts, and by the different Parties in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement, and which shall become effective when one or more counterparts have been signed by each Party and delivered (by facsimile, pdf format, or otherwise) to the other Party.

[Signature pages follow]

2

US-DOCS\112008977.2

IN WITNESS WHEREOF, the parties have executed this Intellectual Property Assignment Agreement as of the date first above written.

THE SELLER:

SIENNA BIOPHARMACEUTICALS, INC.

By:

Name: Frederick Beddingfield III Title: Chief Executive Officer

SIGNATURE PAGE TO INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

THE BUYER:

SEBACIA, INC.

Name: Charles Abraham

Title: Chief Executive Office

REEL: 052138 FRAME: 0385

SCHEDULE 1

Registered Intellectual Property

Topical Photoparticle Therapy TM Patents and Patent Applications Owned by the Seller:

	SIEN.001C2 Thermal Trea	SIEN.001C1 Thermal 7	SIEN.001A Compositions Th		SIEN 001DB3 Compositions		SIEN.001PR2 Compositions	SIEN.001PR Compositions	Ref. No.
Hair Removal With Nanoparticles	Thermal Treatment Of The Skin Surface With Nanoparticles	Thermal Treatment Of Acne With Nanoparticles	Compositions And Methods For Targeted Thermomodulation	Thermoablation	And Methods For Targeted	I hermoablation	Compositions And Methods For Targeted	Compositions And Methods For Targeted Thermoablation	Title
US	US	US	US	C	SII		US	US	Country
Granted / Claim 1 in pending Interference proceeding	Granted	Granted	Granted	(nonprovisional filed)	Closed	(nonprovisional filed)	Closed	Closed (nonprovisional filed)	Status
14/020,481	14/020,387	14/020,423	13/219,514	01/310,300	81/516 308		61/422,612	61/402,305	Application No.
08/26/11 (09/06/13)	08/26/11 (09/06/13)	08/26/11 (09/06/13)	08/26/11	V7/V1/11	04/01/11		12/13/10	08/27/10	Filing Date
8,821,941	8,821,940	8,834,933	9,061,056	11/ a	e/u		n/a	n/a	Patent No.
09/02/14	09/02/14	09/16/14	06/23/15	ша	n/a		n/a	n/a	Issue Date

14/471,367
14/471,268
14/471,331
14/471,350
14/471,434
14/471,319
14/471,330
14/471,377
14/471,348
14/020,599

		1		T			
SIEN.001EPD4	SIEN.001EPD3	SIEN.001EPD2	SIEN.001EPD1	SIEN.001EP	SIEN.001CND1	SIEN.001CN	SIEN.001CA
Compositions And Methods For Targeted Thermomodulation							
Europe	Europe	Europe	Europe	Europe	China	China	Canada
Pending	Granted (with 18 Validations §§§3)	Pending	Granted (with 21 Validations ^{§§2})	Granted (with 21 Validations ^{§1})	Pending	Granted	Pending
19209095.9	17167546.5	17167244.7	17167242.1	11820765.3	201710456429.5	201180041302.8	2,806,592
08/26/11 (11/14/19)	08/26/11 (04/21/17)	08/26/11 (04/20/17)	08/26/11 (04/20/17)	08/26/11	08/26/11 (06/16/17)	08/26/11 (02/26/13)	08/26/11 (01/24/13)
	3210591		3222266	2608762		ZL 20118 0041302.8	
	01/02/19		04/18/18	07/19/17		07/14/17	

¹ § EP2608762 21 European validations in France, Germany, Ireland, Italy, Monaco, Netherlands, Spain, Sweden, Switzerland (& Liechtenstein), United Kingdom, Turkey, Norway, Poland, Austria, Greece, Hungary, Belgium, Czech Republic, Romania, Denmark, and Finland

² §§ EP3222266 21 European validations in France, Germany, Ireland, Italy, Monaco, Netherlands, Spain, Sweden, Switzerland (& Liechtenstein), United Kingdom, Turkey, Norway, Poland, Austria, Greece, Hungary, Belgium, Czech Republic, Romania, Denmark, and Finland

³ §§§ EP3210591 18 European validations in France, Germany, Ireland, Italy, Monaco, Netherlands, Spain, Sweden, Switzerland (& Liechtenstein), United Kingdom, Turkey, Norway, Poland, Austria, Belgium, Denmark, Finland, and Luxembourg

		08/26/11	2019/040786	Pending	Japan	Compositions And Methods For Targeted Thermomodulation	SIEN.001JPD3
		(10/05/17)				Thermomodulation	
03/15/19	649507	08/26/11	2017/194820	Granted	Japan	Compositions And Methods For Targeted	SIEN.001JPD2
		(05/27/16)				Thermomodulation	
10/13/17	6224773	08/26/11	2016/106112	Granted	Japan	Compositions And Methods For Targeted	SIEN.001JPD1
06/03/16	5945540	08/26/11	2013/526193	Granted	Japan	Compositions And Methods For Targeted Thermomodulation	SIEN.001JP
10/31/19	324132	(02/21/13)	1031/DELINE/2013	Granied	HQIZ	Thermomodulation	SIEN. OOTHN
		08/26/11	224390	Pending	Israel	Compositions And Methods For Targeted Thermomodulation	SIEN.001IL
		08/26/11 (05/17/18)	18106458.2	Pending	Hong Kong (via China)	Compositions And Methods For Targeted Thermomodulation	SIEN.001CNHK D1
		08/26/11 (10/27/17)	17110980.2	Pending	Hong Kong (via EPO)	Compositions And Methods For Targeted Thermomodulation	SIEN.001HKD3
		08/26/11 (10/27/17)	17110988.4	Pending	Hong Kong (via EPO)	Compositions And Methods For Targeted Thermomodulation	SIEN.001HKD2
09/14/18	1237255B	08/26/11 (10/27/17)	17110976.8	Granted	Hong Kong (via EPO)	Compositions And Methods For Targeted Thermomodulation	SIEN.001HKD1
06/02/17	202011111093 2.5	08/26/11 (02/20/17)	2020111110932.5	Granted	Germany (Utility Model)	Compositions And Methods For Targeted Thermomodulation	SIEN.001UMDE2
04/26/17	20201111091 6.3	08/26/11 (02/20/17)	202011110916.3	Granted	Germany (Utility Model)	Compositions And Methods For Targeted Thermomodulation	SIEN.001UMDE

n/a	n/a	08/22/14	PCT/US14/52266	Closed	PCT	Targeted Delivery of Nanoparticles to Skin Surface	SIEN.001P2WO
		07/01/14 (02/14/17)	15/432,073	Pending	US	Ultrasound Delivery Of Nanoparticles	SIEN.001P1C1
02/21/17	9,572,880	07/01/14	14/321,509	Granted	US	Ultrasound Delivery Of Nanoparticles	SIEN.001P1
				(nonprovisional filed)			
n/a	n/a	08/26/13	61/870,103	Closed	SU	Treatment Of Skin Surfaces	SIEN.001PR4
		(03/06/19)					

SIEN.002P1C2		SIEN.002P1C1			SIEN.002WO	Ref. No.	Topical Pho	SIEN.001P2WO	SIEN.001P1C1	SIEN.001P1	
Silver Nanoplate Compositions	And Methods	Silver Nanoplate Compositions		Alid Mellious	Silver Nanoplate Compositions	Title	Topical Photoparticle Therapy $^{ m TM}$ Patents and Patent Applications Co-Owned by th	Targeted Delivery of Nanoparticles to Skin Surface	Ultrasound Delivery Of Nanoparticles	Ultrasound Delivery Of Nanoparticles	
US		US			PCT	Country	ts and Pat	es to Skin	articles	articles	
	Co-owne and na		Co-owns and na	(Entered			ent Applica	PCT	US	US	
Granted	Co-owned by the Seller and nanoComposix	Granted	Co-owned by the Seller and nanoComposix	(Entered National Phase)	Closed	Status	itions Co-Owned	Closed	Pending	Granted	(nonprovisional filed)
14/947,508		14/681,379			PCT/US13/63920	Application No.	by the Seller (the	PCT/US14/52266	15/432,073	14/321,509	
10/08/13	(04/08/15)	10/08/13			10/08/13	Filing Date	"Co-Owner	08/22/14	07/01/14 (02/14/17)	07/01/14	
9,526,745		9,212,294			n/a	Patent No.	ie Seller (the " <u>Co-Owned Patents")</u> :4	n/a		9,572,880	
12/27/16		12/15/15			n/a	Issue Date		n/a		02/21/17	

⁴ **Note:** The Co-Owned Patents are jointly owned by the Seller and nanoComposix, Inc. ("<u>nanoComposix</u>") and are included in the exclusive license granted to the Seller by nanoComposix under the Exclusive License Agreement referenced in Schedule 5.8(c).

		10/08/13 (04/13/18)	2018103329678	Pending Co-owned by the Seller and nanoComposix	China	Silver Nanoplate Compositions And Methods	SIEN.002CND1
	0061329.2	(05/25/15)		Co-owned by the Seller and nanoComposix	CALLER	And Methods	
05/01/18	ZL 20138	(04/08/15)	201380061329 2	Co-owned by the Seller and nanoComposix	China	And Methods Silver Nanoplate Compositions	SIEN 002CN
		10/08/13	2,887,687	Pending	Canada	Silver Nanoplate Compositions	SIEN.002CA
		(04/10/15)		Co-owned by the Seller and nanoComposix		And Methods	
		10/08/13	BR112015008063-4	Pending	Brazil	Silver Nanoplate Compositions	SIEN.002BR
		(10/03/18)		Co-owned by the Seller and nanoComposix		And Methods	
		10/08/13	2018241065	Pending	Australia	Silver Nanoplate Compositions	SIEN.002AUD2
		(08/28/17)		Co-owned by the Seller and nanoComposix		And Methods	
10/18/18	2017219126	10/08/13	2017219126	Granted	Australia	Silver Nanoplate Compositions	SIEN.002AUD1
		(04/28/15)		Co-owned by the Seller and nanoComposix		And Methods	
10/05/17	2013329450	10/08/13	2013329450	Granted	Australia	Silver Nanoplate Compositions	SIEN.002AU
		(12/09/16)		Co-owned by the Seller and nanoComposix		And Methods	
		10/08/13	15/374,942	Pending	US	Silver Nanoplate Compositions	SIEN.002P1C3
		(11/20/15)		Co-owned by the Seller and nanoComposix		And Methods	

		T		Т				П			T		-		
SIEN.002JPD1		SIEN.002JP		SIEN.002IN		SIEN.002IL		SIEN.002EPD1			SIEN.002EP		SIEN.002HKD1		SIEN.002HK
Silver Nanoplate Compositions	And Methods	Silver Nanoplate Compositions		And Methods	Silver Nanoplate Compositions	And Methods	Silver Nanoplate Compositions	OTIM MACHIONS	Silver Nanoplate Compositions						
Japan		Japan		India		Israel		Europe			Europe	(via China)	Hong Kong	(via Cillia)	Hong Kong
Pending	Co-owned by the Seller and nanoComposix	Granted	Co-owned by the Seller and nanoComposix	Pending	Co-owned by the Seller and nanoComposix	Pending	Co-owned by the Seller and nanoComposix	Pending	Co-owned by the Seller and nanoComposix	(with 15 Validations §§§§5)	Granted	Co-owned by the Seller and nanoComposix	Pending	Co-owned by the Seller and nanoComposix	Granted
2018-76470		2015-536844		3682/DELNP/2015		238112		17174462.6			13845112.5		18113304.4		16100850.1
10/08/13	(04/08/15)	10/08/13	(04/30/15)	10/08/13	(04/02/15)	10/08/13	(06/03/1/)	10/08/13		(05/01/15)	10/08/13	(10/1//18)	10/08/13	(01/20/10)	10/08/13
		6325552									2906286				1212931B
		04/20/18									06/14/17				09/29/18

⁵ §§§ EP2906286 15 European validations in France, Germany, Ireland, Italy, Monaco, Netherlands, Spain, Sweden, Switzerland (& Liechtenstein), United Kingdom, Turkey, Norway, Denmark, Finland, and Poland

SIE	SIEN	SIE	SIE	SIE	
SIEN.002KR	SIEN.002RUD1	SIEN.002RU	SIEN.002MX	SIEN.002JPD2	
Silver Nanoplate Compositions And Methods	And Methods				
South Korea	Russian Federation	Russian Federation	Mexico	Japan	
Pending Co-owned by the Seller and nanoComposix	Pending Co-owned by the Seller and nanoComposix	Granted Co-owned by the Seller and nanoComposix	Pending Co-owned by the Seller and nanoComposix	Pending Co-owned by the Seller and nanoComposix	Co-owned by the Seller and nanoComposix
10-2015-7012210	2018106951	2015112182	MX/a/2015/004524	2019-149791	
10/08/13 (05/08/15)	10/08/13 (02/26/18)	10/08/13	10/08/13 (04/09/15)	10/08/13 (08/19/19)	(04/12/18)
		2646809			
		03/07/18			

Trade

SIEN.016T	Topical Photoparticle Therapy™ Platform	Ref. No.
-	icle Therapy™	•
TPT	Platform	Mark
United States		Country
Registered		Status
86/465789		No./ Filing Date
5,492,455 06/12/18		Reg. No./Date

SIEN.016ICH			SIEN.016IAU		SIEN.016WWO	SIEN.016WPH		SIEN.016WCA2		SIEN.022WBR		SIEN.021WBR		SIEN.016WBR		SIEN.021WAR		SIEN.016WAR
ТРТ			ТРТ		TPT	ТРТ		TPT		TPT		TPT		TPT		TPT		TPT
Switzerland*			Australia*	(Intl.)	Madrid System	Philippines		Canada		Brazil		Brazil		Brazil		Argentina		Argentina
Registered			Registered	designations below)	(see *	Registered		Pending		Registered								
1266578		05/20/15	1266578	05/20/15	1266578	4-2018- 021377 11/28/18	05/19/17	1839809	05/26/15	909432074	05/26/15	909431949	05/26/15	909431795	05/17/17	3604443	05/17/17	3604442
1266578	01/22/16	1725115	1266578	10/01/15	1266578	4-2018-021377 05/19/19			09/04/18	909432074	09/04/18	909431949	09/04/18	909431795	10/22/18	2959871	10/22/18	2959870

11/23/16					
1676646	05/20/15				
IR 1266578	1266578	Registered	Mexico*	ТРТ	SIEN.016IMX
11/06/17	05/19/17				
1266578	1266578	Registered	Monaco*	ТРТ	SIEN.016IMC
05/31/16	05/20/15				
1266578	1266578	Registered	South Korea*	TPT	SIEN.016IKR
02/25/16	05/20/15				
1266578	1266578	Registered	Japan*	TPT	SIEN.016IJP
02/17/19	05/19/17				
1266578	1266578	Registered	India*	ТРТ	SIEN.016IIN2
05/03/17	05/20/15				
1266578	1266578	Registered	lsrael*	ТРТ	SIEN.016IIL
08/03/16	05/20/15		Union*		
1266578	1266578	Registered	European	ТРТ	SIEN.016IEM
09/14/17					
1266578 571302	05/20/15				
	1266578	Registered	Colombia*	ТРТ	SIEN.016ICO
11/23/16	05/20/15				
1266578	1266578	Registered	China*	ТРТ	SIEN.016ICN
09/02/16	05/20/15				

			<u>S</u>		S			SI			SI		SI			SI			Č
SIEN.073T	SIEN.072T		SIEN.016IVN		SIEN.016ITR			SIEN.016ISG			SIEN.016INZ		SIEN.016INO			SIEN.016IMX			SICIN.O FOLINIX
SCIENCE OF SILVER	SCIENCE OF SILVER	;	TPT		Ibl			ТРТ			ТРТ		TPT			ТРТ			= -
United States	United States		Vietnam*		Turkev*			Singapore*			New Zealand*		Norway*			Mexico*			INICAICO
Registered	Registered	0	Registered	C	Registered			Registered			Registered		Registered			Registered			Ivegistered
87/475451	87/475432 06/05/17	05/20/15	1266578	05/20/15	1266578		05/20/15	1266578		05/20/15	1266578	05/20/15	1266578		05/20/15	1266578		05/20/15	1200770
5,581,724 10/09/18	5,551,871 08/28/18	10/01/16	1266578	09/10/16	1266578	02/19/16	40201517343U	1266578	02/02/16	1028826	1266578	05/13/16	1266578	11/23/16	1676648	IR 1266578	11/23/16	1676647	17.

														-	
SIEN.073IJP	SIEN.073IIL	SIEN.073IIN	SIEN.073IEM	SIEN.073ICO	SIEN.073ICN			SIEN.073IAU		SIEN 073WWO	SIEN.073WCA		SIEN.073WBR	SIEN.073WAR	
SCIENCE OF SILVER			SCIENCE OF SILVER		SCIENCE OF SILVER	SCIENCE OF SILVER		SCIENCE OF SILVER	SCIENCE OF SILVER						
Japan*	srae *	India*	European Union*	Colombia*	China*			Australia*	(Intl.)	Madrid System	Canada		Brazil	Argentina	
Registered	Registered	Registered	Registered	Registered	Registered		ţ	Registered	designations below)	(SAB *	Pending	(Registered	Pending	
1385385 11/30/17	1385385 11/30/17	1385385 11/30/17	1385385 11/30/17	1385385 11/30/17	1385385 11/30/17		11/30/17	1385385	11/30/17	1385385	1871734 12/01/17	12/04/17	913835188	3665732 12/01/17	06/05/17
1385385 08/30/18	1385385 02/05/19	1385385 09/23/19	1385385 07/30/18	1385385 03/19/19	1385385 12/05/18	08/17/18	1902421	1385385	01/25/18	1385385		01/08/19	913835188		

SIEN.073ICH		SIEN.073ISG	SIEN.073IRU	SIEN.073IPH	SIEN.073INO			SIEN.073INZ	SIEN.073IMC	SIEN.073IMX	SIEN.073IMX	SIEN.073IKR
SCIENCE OF SILVER		SCIENCE OF SILVER	SCIENCE OF SILVER	SCIENCE OF SILVER	SCIENCE OF SILVER			SCIENCE OF SILVER	SCIENCE OF SILVER	SCIENCE OF SILVER	SCIENCE OF SILVER	SCIENCE OF SILVER
Switzerland*		Singapore*	Russia*	Philippines*	Norway*			New Zealand*	Monaco*	Mexico*	Mexico*	South Korea*
Registered		Registered	Registered	Pending	Registered			Registered	Registered	Registered	Registered	Registered
1385385 11/30/17		1385385 11/30/17	1385385 11/30/17	1385385 11/30/17	1385385 11/30/17			1385385 11/30/17	1385385 11/30/17	1385385 11/30/17	1385385 11/30/17	1385385 11/30/17
1385385 01/04/19	07/19/18	1385385 40201801603T	1385385 09/21/18		1385385 01/18/19	06/01/18	1385385	1085309	1385385 03/26/18	1944260 1385385 12/16/18	1944259 1385385 12/16/18	1385385 11/12/18

07/25/19	11/30/17				
1385385	1385385	Registered	Vietnam*	SCIENCE OF SILVER	NAIE20'NBIS
11/29/18	11/30/17				
1385385	1385385	Registered	Turkey*	SCIENCE OF SILVER	SIEN.073ITR